128 related articles for article (PubMed ID: 8556394)
1. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.
Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394
[TBL] [Abstract][Full Text] [Related]
2. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients.
Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL
J Infect Dis; 1995 Jun; 171(6):1420-30. PubMed ID: 7769275
[TBL] [Abstract][Full Text] [Related]
4. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
[TBL] [Abstract][Full Text] [Related]
5. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
Trujillo JR; Rogers RA; Brain JD
Virology; 1998 Jun; 246(1):53-62. PubMed ID: 9656993
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive T-cell epitope mapping of HIV-1 env antigens reveals many areas recognized by HIV-1-seropositive and by low-risk HIV-1-seronegative individuals.
Mutch D; Underwood J; Geysen M; Rodda S
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):879-90. PubMed ID: 7519672
[TBL] [Abstract][Full Text] [Related]
7. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase.
Lieberman J; Fabry JA; Kuo MC; Earl P; Moss B; Skolnik PR
J Immunol; 1992 May; 148(9):2738-47. PubMed ID: 1374097
[TBL] [Abstract][Full Text] [Related]
9. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
11. Class II (I-Ad) restricted T-cell recognition of the V3 loop region of HIV-1 gp120.
Warren AP; Thomas DB
AIDS Res Hum Retroviruses; 1992 May; 8(5):559-64. PubMed ID: 1381202
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression.
Goudsmit J
Int Rev Immunol; 1992; 8(1):65-81. PubMed ID: 1374113
[TBL] [Abstract][Full Text] [Related]
13. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
Wahren B; Bratt G; Persson C; Levén B; Hinkula J; Gilljam G; Nordlund S; Eriksson L; Volvovitz F; Broliden PA
J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):220-9. PubMed ID: 7906300
[TBL] [Abstract][Full Text] [Related]
14. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.
Wagner R; Böltz T; Deml L; Modrow S; Wolf H
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1261-9. PubMed ID: 7687647
[TBL] [Abstract][Full Text] [Related]
15. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
16. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes.
Chesebro B; Wehrly K; Nishio J; Perryman S
J Virol; 1996 Dec; 70(12):9055-9. PubMed ID: 8971043
[TBL] [Abstract][Full Text] [Related]
17. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation.
Moore RL; Fox BS
AIDS Res Hum Retroviruses; 1993 Jan; 9(1):51-9. PubMed ID: 7678972
[TBL] [Abstract][Full Text] [Related]
18. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
19. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1.
Casement KS; Nehete PN; Arlinghaus RB; Sastry KJ
Virology; 1995 Aug; 211(1):261-7. PubMed ID: 7645219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
